Please assess the completion status of the following clinical trial:

Trial Title: High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, age 12 to 65 years.~2. Patients with seminomatous or nonseminomatous germ-cell tumors (GCT) in one of the following groups: A) First relapse or progression or second response with an intermediate or high risk according to the Beyer model. B) Second relapse or beyond.~3. Adequate renal glomerular and tubular function, as defined by estimated serum creatinine clearance \>/=50 ml/min and/or serum creatinine \</= 1.8 mg/dL, and urinary protein excretion \</=500 mg/day.~4. Adequate hepatic function, as defined by ALT and AST \</=3 x upper limit of normal (ULN); serum bilirubin and alkaline phosphatase \</=2 x ULN or considered not clinically significant.~5. Adequate pulmonary function with FEV1 (Forced expiratory volume in the first second), FVC (Forced vital capacity) and DLCO (diffusing capacity of the lung for carbon monoxide) \>/=50% of predicted, corrected for volume and hemoglobin.~6. Adequate cardiac function with LVEF (left ventricular ejection fraction) \>/=40%. No uncontrolled arrhythmias or symptomatic cardiac disease.~7. Zubrod performance status 0-2.~8. A minimum apheresis collection of 5 million CD34+ cells/kg of autologous hematopoietic progenitor cells (AHPC).~9. Written informed consent by patients and/ or their parents or legal guardians. Assent for those patients inclusive of ages 12 to 17.~Exclusion Criteria:~1. Growing teratoma syndrome, defined as enlarging tumor masses with normal serum markers during chemotherapy for nonseminomatous GCT.~2. Major surgery within 30 days before the initiation of study treatment~3. Radiotherapy within 21 days prior to initiation of study treatment~4. Prior whole brain irradiation.~5. Patients with active central nervous system (CNS) disease, defined as brain or meningeal metastases that are not in complete remission.~6. Patients with active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA \>/=10,000 copies/mL, or \>/= 2,000 IU/mL).~7. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients who either show chronic hepatitis C or positive hepatitis C serology.~8. Active infection requiring parenteral antibiotics.~9. HIV infection, unless the patient is receiving effective antiretroviral therapy with undetectable viral load and normal CD4 counts~10. Patients who have had a previous autologous or allogeneic stem cell transplant in the previous 12 months.~11. Positive pregnancy test in a female patient of childbearing potential defined as not post menopausal for twelve months or no previous surgical sterilization.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cycle # 1 (Type: EXPERIMENTAL): First Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)~HD Cycle #1: Gemcitabine/Docetaxel/Melphalan/Carboplatin + PBPC
- Cycle #2 (Type: EXPERIMENTAL): Second Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)~HD Cycle #2: Ifosfamide/Carboplatin/Etoposide + PBPC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete